Livzon Pharmaceutical Group000513.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Livzon Pharmaceutical Group (000513.SZ) trades at a P/E of 14.80x, P/B of 1.86x, P/S of 2.48x, and a dividend yield of 5.80%.
Longitudinal percentile comparison: P/E sits at the 16th percentile over the trailing 10Y window (vs. 20th percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 9th percentile over 3Y); P/S sits at the 13th percentile over the trailing 10Y window (vs. 19th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 9th percentile within its industry and the 13th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 8.41%, ranking at the 99th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 12.2 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 5.80% comes from cash dividends, with an implied ~2.62% from buybacks — a fairly balanced mix of both channels. Livzon Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 000513 · SZSE: 000513 · 000513
Want the full picture on whether Livzon Pharmaceutical Group (000513.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 14.80 | ||||||
| P/B (MRQ) | 1.86 | ||||||
| P/S (TTM) | 2.48 | ||||||
| Dividend Yield | 5.80% | ||||||
| Buyback + Div Yield | 8.41% |